Why Veracyte Stock Is Skyrocketing Higher This Week

Veracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned. Sales for the company's main prostate and thyroid cancer-detecting tests continue to grow by double-digit rates.